Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$36.35 +0.9%	$39.78	$26.20 ▼ $63.50	$1.68B	1.43	740,633 shs	484,772 shs
BEAM Beam Therapeutics	$16.01 -0.3%	$18.74	$13.52 ▼ $35.25	$1.62B	2.22	2.10 million shs	2.48 million shs
DYN Dyne Therapeutics	$12.22 +2.1%	$10.32	$6.36 ▼ $47.06	$1.74B	1.08	2.63 million shs	1.60 million shs
GOSS Gossamer Bio	$2.17 +11.3%	$1.61	$0.66 ▼ $2.23	$493.42M	1.96	1.95 million shs	4.42 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	-1.07%	-3.62%	-7.90%	-10.75%	-26.47%
BEAM Beam Therapeutics	-1.77%	-8.33%	-23.63%	-6.84%	-34.53%
DYN Dyne Therapeutics	-2.29%	-2.21%	+30.53%	+0.59%	-74.43%
GOSS Gossamer Bio	+1.56%	-1.02%	+11.43%	+68.10%	+109.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APGE Apogee Therapeutics	3.4419 of 5 stars	4.4	3.0	0.0	1.0	4.2	0.0
BEAM Beam Therapeutics	2.2135 of 5 stars	3.5	0.0	0.0	2.5	2.5	0.6
DYN Dyne Therapeutics	3.0798 of 5 stars	4.5	1.0	0.0	1.3	4.2	0.0
GOSS Gossamer Bio	3.5663 of 5 stars	3.5	1.0	4.7	1.4	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	2.86	Moderate Buy	$99.00	171.90% Upside
BEAM Beam Therapeutics	3.07	Buy	$48.45	202.84% Upside
DYN Dyne Therapeutics	3.00	Buy	$33.80	176.48% Upside
GOSS Gossamer Bio	3.00	Buy	$8.50	290.80% Upside

Current Analyst Ratings Breakdown

Latest GOSS, DYN, BEAM, and APGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	APGE Apogee Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2025	APGE Apogee Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
8/6/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $21.00
8/6/2025	DYN Dyne Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $13.00
8/6/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $5.00
7/31/2025	DYN Dyne Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$66.00 ➝ $36.00
7/29/2025	DYN Dyne Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $23.00
7/29/2025	DYN Dyne Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$37.00 ➝ $31.00
7/29/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $38.00
7/21/2025	BEAM Beam Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/15/2025	DYN Dyne Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$13.43 per share	N/A
BEAM Beam Therapeutics	$63.52M	25.48	N/A	N/A	$10.35 per share	1.55
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$4.02 per share	N/A
GOSS Gossamer Bio	$114.70M	4.31	N/A	N/A	($0.20) per share	-10.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$182.15M	-$4.13	N/A	N/A	N/A	N/A	-34.65%	-32.76%	N/A
BEAM Beam Therapeutics	-$376.74M	-$4.50	N/A	N/A	N/A	-661.31%	-43.15%	-31.06%	11/4/2025 (Estimated)
DYN Dyne Therapeutics	-$317.42M	-$3.86	N/A	N/A	N/A	N/A	-64.12%	-56.75%	N/A
GOSS Gossamer Bio	-$56.53M	-$0.62	N/A	N/A	N/A	-344.81%	-1,774.72%	-46.73%	11/6/2025 (Estimated)

Latest GOSS, DYN, BEAM, and APGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	APGE Apogee Therapeutics	-$1.03	-$1.13	-$0.10	-$1.13	N/A	N/A
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	-$1.00	+$0.04	-$1.00	$13.29 million	$8.47 million
8/5/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	-$0.17	+$0.01	-$0.17	$4.12 million	$11.49 million
7/28/2025	Q2 2025	DYN Dyne Therapeutics	-$0.99	-$0.97	+$0.02	-$0.97	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	16.36	16.36
BEAM Beam Therapeutics	N/A	6.75	6.75
DYN Dyne Therapeutics	0.17	16.83	16.83
GOSS Gossamer Bio	6.70	4.40	4.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
BEAM Beam Therapeutics	99.68%
DYN Dyne Therapeutics	96.68%
GOSS Gossamer Bio	81.23%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	42.77%
BEAM Beam Therapeutics	3.50%
DYN Dyne Therapeutics	14.14%
GOSS Gossamer Bio	6.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	46.11 million	26.39 million	Optionable
BEAM Beam Therapeutics	510	101.16 million	97.62 million	Optionable
DYN Dyne Therapeutics	100	142.26 million	122.15 million	Optionable
GOSS Gossamer Bio	180	227.38 million	212.15 million	Optionable

GOSS, DYN, BEAM, and APGE Headlines

Recent News About These Companies

H.C. Wainwright and Leerink Partners Reiterate ‘Buy’ Ratings on Gossamer Bio, Inc. (GOSS)

August 19 at 2:31 AM | finance.yahoo.com

Analysts' Revenue Estimates For Gossamer Bio, Inc. (NASDAQ:GOSS) Are Surging Higher

August 15, 2025 | finance.yahoo.com

Gossamer Bio Reports Q2 2025 Financial Results

August 12, 2025 | msn.com

Gossamer Bio (NASDAQ:GOSS) Cut to Sell at Wall Street Zen

August 12, 2025 | americanbankingnews.com

Wedbush Brokers Increase Earnings Estimates for Gossamer Bio

August 12, 2025 | americanbankingnews.com

Institutional investors in Gossamer Bio, Inc. (NASDAQ:GOSS) see US$54m decrease in market cap last week, although long-term gains have benefitted them.

August 11, 2025 | finance.yahoo.com

HC Wainwright Has Positive View of Gossamer Bio Q3 Earnings

August 11, 2025 | americanbankingnews.com

Q3 EPS Estimates for Gossamer Bio Increased by HC Wainwright

August 11, 2025 | marketbeat.com

Wedbush Has Optimistic Outlook of Gossamer Bio Q3 Earnings

August 11, 2025 | marketbeat.com

Gossamer Bio (NASDAQ:GOSS) Stock Rating Lowered by Wall Street Zen

August 10, 2025 | marketbeat.com

Leerink Partners Sticks to Its Buy Rating for Gossamer Bio (GOSS)

August 9, 2025 | theglobeandmail.com

Q3 EPS Estimates for Gossamer Bio Reduced by Leerink Partnrs

August 9, 2025 | marketbeat.com

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 7, 2025 | businesswire.com

Wedbush Boosts Gossamer Bio (NASDAQ:GOSS) Price Target to $5.00

August 7, 2025 | marketbeat.com

FY2025 EPS Estimates for Gossamer Bio Boosted by Analyst

August 7, 2025 | marketbeat.com

Gossamer Bio (NASDAQ:GOSS) Issues Earnings Results, Beats Expectations By $0.01 EPS

August 6, 2025 | marketbeat.com

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

August 5, 2025 | bakersfield.comB

Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates

August 5, 2025 | zacks.com

Gossamer Bio (GOSS) Expected to Announce Quarterly Earnings on Monday

August 5, 2025 | marketbeat.com

Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Sold by GSA Capital Partners LLP

August 3, 2025 | marketbeat.com

Scotiabank Initiates Outperform on Gossamer Bio (GOSS) with an $11 PT, Highlights Potential of PAH Drug Seralutinib

August 1, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GOSS, DYN, BEAM, and APGE Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$36.35 +0.33 (+0.92%)

Closing price 04:00 PM Eastern

Extended Trading

$36.42 +0.07 (+0.19%)

As of 04:30 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Beam Therapeutics NASDAQ:BEAM

$16.01 -0.05 (-0.31%)

Closing price 04:00 PM Eastern

Extended Trading

$16.00 -0.01 (-0.03%)

As of 07:32 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Dyne Therapeutics NASDAQ:DYN

$12.22 +0.25 (+2.09%)

Closing price 04:00 PM Eastern

Extended Trading

$12.23 +0.01 (+0.08%)

As of 06:03 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Gossamer Bio NASDAQ:GOSS

$2.17 +0.22 (+11.28%)

Closing price 04:00 PM Eastern

Extended Trading

$1.95 -0.22 (-10.14%)

As of 07:31 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time